Renal and neurological response with eculizumab in a patient with transplant associated thrombotic microangiopathy after allogeneic hematopoietic progenitor cell transplantation.

Abstract

Transplantation-associated thrombotic microangiopathy (TA-TMA) is a challenge after allogeneic hematopoietic progenitor cell transplantation, considering the diagnostic uncertainties and lack of established treatment. We report a 43-year-old male patient who was diagnosed as TA-TMA after allogeneic progenitor cell transplantation for a progressive ALK negative anaplastic large cell lymphoma and responded to eculizumab with dramatically improving neurological status and renal function. Rapid neurological and renal recovery achieved after eculizumab could support a possible relationship between complement activation and TA-TMA. Eculizumab should be a reasonable treatment approach in patients with TA-TMA after allogeneic hematopoietic progenitor cell transplantation.

• Authors: Ömür Gökmen Sevindik, İnci Alacacıoğlu, Abdullah Katgı, Şerife Medeni Solmaz, Celal Acar, Özden Pişkin, Mehmet Ali Özcan, Fatih Demirkan, Bülent Ündar, Güner Hayri Özsan
• Journal: Case reports in hematology (Case Rep Hematol) Vol. 2015 Pg. 425410 ( 2015) ISSN: 2090-6560 [Print] United States
• PMID: 25705530 (Publication Type: Journal Article)